scholarly journals 88 Lowe syndrome – old and new evidence of secondary mitochondrial dysfunction

Author(s):  
Katja Dumic Kubat ◽  
Darko Anticevic ◽  
Jelena Petrinovic-Doresic ◽  
Tamara Zigman ◽  
Kamelija Zarković ◽  
...  
2020 ◽  
Vol 63 (10) ◽  
pp. 104022
Author(s):  
Katja K. Dumic ◽  
Darko Anticevic ◽  
Jelena Petrinovic-Doresic ◽  
Tamara Zigman ◽  
Kamelija Zarković ◽  
...  

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Salva R. Yurista ◽  
Herman H. W. Silljé ◽  
Michiel Rienstra ◽  
Rudolf A. de Boer ◽  
B. Daan Westenbrink

AbstractWhile patients with type 2 diabetes mellitus (T2DM) are at increased risk to develop atrial fibrillation (AF), the mechanistic link between T2DM and AF-susceptibility remains unclear. Common co-morbidities of T2DM, particularly hypertension, may drive AF in the setting of T2DM. But direct mechanisms may also explain this relation, at least in part. In this regard, recent evidence suggests that mitochondrial dysfunction drives structural, electrical and contractile remodelling of atrial tissue in patients T2DM. Mitochondrial dysfunction may therefore be the mechanistic link between T2DM and AF and could also serve as a therapeutic target. An elegant series of experiments published in Cardiovascular Diabetology provide compelling new evidence to support this hypothesis. Using a model of high fat diet (HFD) and low-dose streptozotocin (STZ) injection, Shao et al. provide data that demonstrate a direct association between mitochondrial dysfunction and the susceptibility to develop AF. But the authors also demonstrated that the sodium-glucose co-transporter 2 inhibitors (SGLT2i) empagliflozin has the capacity to restore mitochondrial function, ameliorate electrical and structural remodelling and prevent AF. These findings provide a new horizon in which mitochondrial targeted therapies could serve as a new class of antiarrhythmic drugs.


2012 ◽  
Vol 27 (9) ◽  
pp. 1223-1229 ◽  
Author(s):  
David R. Lynch ◽  
Eric C. Deutsch ◽  
Robert B. Wilson ◽  
Gihan Tennekoon

During the past 15 years, the pace of research advancement in Friedreich ataxia has been rapid. The abnormal gene has been discovered and its gene product characterized, leading to the development of new evidence-based therapies. Still, various unsettled issues remain that affect clinical trials. These include the level of frataxin deficiency needed to cause disease, the mechanism by which frataxin-deficient mitochondrial dysfunction leads to symptomatology, and the reason selected cells are most affected in Friedreich ataxia. In this review, we summarize these questions and propose testable hypotheses for their resolution.


Hypertension ◽  
2020 ◽  
Vol 76 (Suppl_1) ◽  
Author(s):  
Xiao C Li ◽  
Xinchun Zhou ◽  
Jia L Zhuo

Angiotensin II (Ang II) has long been implicated in mediating mitochondrial dysfunction in cardiovascular, hypertension, and kidney diseases. However, whether it is circulating and paracrine Ang II or intracellular mitochondrial Ang II that induces mitochondrial dysfunction has not been studied previously. The present study tested the hypotheses that overexpression of an intracellular angiotensin II (Ang II) fusion protein, mito-ECFP/Ang II, selectively in the mitochondria of mouse proximal tubule (mPCT) cells induces mitochondrial oxidative and glycolytic responses and elevates blood pressure via the Ang II/AT 1a receptor/superoxide/NHE3 (the Na + /H + exchanger 3)-dependent mechanisms. A proximal tubule-selective, mitochondria-targeting adenoviral construct encoding Ad-sglt2-mito-ECFP/Ang II was used to test the hypotheses. The expression of mito-ECFP/Ang II was colocalized primarily with Mito-Tracker® Red FM in mPCT cells or with TMRM in kidney proximal tubules. mito-ECFP/Ang II markedly increased oxygen consumption rate (OCR) as an index of mitochondrial oxidative response (69.5%; P <0.01) and extracellular acidification rate (ECAR) as an index of mitochondrial glycolytic response (34%; P <0.01). The mito-ECFP/Ang II-induced OCR and ECAR responses were blocked by AT 1 blocker losartan ( P <0.01) and a mitochondria-targeting superoxide scavenger mito-TEMPO ( P <0.01). By contrast, the non-selective NO inhibitor L-NAME alone increased, whereas the mitochondria-targeting expression of AT 2 receptors (mito-AT 2 /GFP) attenuated the effects of mito-ECFP/Ang II ( P <0.01). In the kidney, overexpression of mito-ECFP/Ang II in the mitochondria of the proximal tubules increased systolic blood pressure 12 ± 3 mmHg ( P <0.01), and the response was attenuated in proximal tubule (PT)-specific PT- Agtr1a -/- and PT- Nhe3 -/- mice ( P <0.01). Conversely, overexpression of AT 2 receptors selectively in the mitochondria of the proximal tubules induced natriuretic responses in PT- Agtr1a -/- and PT- Nhe3 -/- mice ( P <0.01). Taken together, these results provide new evidence for a physiological role of proximal tubule mitochondrial Ang II/AT 1a /superoxide/NHE3 and Ang II/AT 2 /NO/NHE3 signaling pathways in maintaining blood pressure homeostasis.


2021 ◽  
pp. 1-8
Author(s):  
Xilma R. Ortiz-González

Mitochondria, the organelles classically seen as the powerhouse of the cell, are increasingly associated with a wide variety of neurodevelopmental disorders. Although individually rare, a myriad of pediatric neurogenetic disorders have been identified in the last few years, thanks to advances in clinical genetic sequencing and data analysis. As this exponential growth continues, mitochondrial dysfunction is increasingly implicated in childhood neurodevelopmental disorders, with clinical presentations ranging from syndromic autism, intellectual disability, and epileptic encephalopathies to childhood onset neurodegeneration. Here we review recent evidence demonstrating mitochondrial involvement in neurodevelopmental disorders, identify emerging mechanistic trends, and reconsider the long-standing question of the role of mitochondria in light of new evidence: causation versus mere association.


1978 ◽  
Vol 48 ◽  
pp. 31-35
Author(s):  
R. B. Hanson

Several outstanding problems affecting the existing parallaxes should be resolved to form a coherent system for the new General Catalogue proposed by van Altena, as well as to improve luminosity calibrations and other parallax applications. Lutz has reviewed several of these problems, such as: (A) systematic differences between observatories, (B) external error estimates, (C) the absolute zero point, and (D) systematic observational effects (in right ascension, declination, apparent magnitude, etc.). Here we explore the use of cluster and spectroscopic parallaxes, and the distributions of observed parallaxes, to bring new evidence to bear on these classic problems. Several preliminary results have been obtained.


2007 ◽  
Vol 40 (9) ◽  
pp. 36
Author(s):  
BRUCE JANCIN
Keyword(s):  

2001 ◽  
Vol 58 (6) ◽  
pp. 362-366 ◽  
Author(s):  
Matius P. Stürchler ◽  
R. P. Steffen
Keyword(s):  

Impfungen sind einfache und effektive Maßnahmen zur Verhinderung von Reisekrankheiten. Compliance-Probleme sind gering, da alle Impfungen noch vor Abreise verabreicht werden und bei manchen Impfungen nur eine Dosis für den zuverlässigen Schutz nötig ist. Für jeden Reisenden sind die Hepatitis A- und die Diphtherie-Tetanus-Impfung empfohlen, für Asien und Afrika auch die Polioimpfung. Bei Reisen >30 Tagen, jüngeren Personen und Reisenden mit Risikoverhalten sollte immer auch eine Hepatitis B-Impfung, eventuell als Kombination mit Hepatitis A in Betracht gezogen werden. Je nach Reisestil, -destination und -dauer können auch weitere Impfungen wie z.B. die Typhus-, Tollwut-, Zeckenenzephalitis-, Grippe-, Masern-Mumps-Röteln-, Gelbfieber-, Meningokokkenmeningitis- und die Japanische Enzephalitis-Impfung in Frage kommen. Mehrere Impfungen können gleichzeitig verabreicht werden – eine Staffelung ist nicht nötig. i BAG Supplementum VI, Stand Juli 2000 «Impfungen für Auslandreisende»; http://www.admin.ch/bag/infekt/prev/reisemed/index.htm; Safetravel http://www.safetravel.ch; Tropimed


Sign in / Sign up

Export Citation Format

Share Document